Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Nadia Cano Vazquez

Nurse Practitioner Albuquerque, NM Nurse Practitioner

NPI 1174007561 CMS profile 10979865

2211 Lomas Blvd Ne, Albuquerque, NM 87106

Open in the dashboard

General payments

$5,833

362 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Nadia Cano Vazquez of Albuquerque, NM is reported in the CMS Open Payments database as having received $5,833 across 362 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,480 83
2022 General $2,108 136
2021 General $2,245 143

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nadia Cano Vazquez
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Nadia Cano Vazquez were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Nadia Cano Vazquez Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,245 $135 $40–$426 $132
2022 $2,108 $152 $48–$470 $149
2023 $1,480 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Lilly USA, LLC $718 46 payments
  2. Corcept Therapeutics $588 36 payments
  3. Novo Nordisk Inc $560 32 payments
  4. Insulet Corporation $536 26 payments
  5. Antares Pharma, Inc. $380 40 payments
  6. AstraZeneca Pharmaceuticals LP $313 19 payments
  7. Radius Health, Inc. $281 17 payments
  8. AbbVie, Inc. $244 16 payments
  9. Amgen Inc. $186 11 payments
  10. Dexcom, Inc. $177 11 payments
  11. Other $1,848 108 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $5,819 361 payments
  2. Education $14 1 payment
Products named General payments · program years 2021–2023
  1. Korlym $588 36 payments
  2. Omnipod $536 26 payments
  3. Ozempic $440 24 payments
  4. RYBELSUS $401 22 payments
  5. FARXIGA $313 19 payments
  6. XYOSTED $279 28 payments
  7. JARDIANCE $262 17 payments
  8. NOCDURNA $260 27 payments
  9. SYNTHROID $223 15 payments
  10. TLANDO $222 20 payments
  11. Other $3,628 221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

30

Median for Nurse Practitioner: 389

Drug cost

$1,273

Median for Nurse Practitioner: $21,885

Branded share of claims

36.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nano 2nd Gen Pen Needle Pen Needle, Diabetic Brand 11 $1,082
Levothyroxine Sodium Generic 19 $190

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

362 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record